Literature DB >> 25870266

Post-treatment control of HIV infection.

Jessica M Conway1, Alan S Perelson2.   

Abstract

Antiretroviral therapy (ART) for HIV is not a cure. However, recent studies suggest that ART, initiated early during primary infection, may induce post-treatment control (PTC) of HIV infection with HIV RNA maintained at <50 copies per mL. We investigate the hypothesis that ART initiated early during primary infection permits PTC by limiting the size of the latent reservoir, which, if small enough at treatment termination, may allow the adaptive immune response to prevent viral rebound (VR) and control infection. We use a mathematical model of within host HIV dynamics to capture interactions among target cells, productively infected cells, latently infected cells, virus, and cytotoxic T lymphocytes (CTLs). Analysis of our model reveals a range in CTL response strengths where a patient may show either VR or PTC, depending on the size of the latent reservoir at treatment termination. Below this range, patients will always rebound, whereas above this range, patients are predicted to behave like elite controllers. Using data on latent reservoir sizes in patients treated during primary infection, we also predict population-level VR times for noncontrollers consistent with observations.

Entities:  

Keywords:  HIV latency; HIV viral rebound; immune exhaustion; mathematical modeling

Mesh:

Year:  2015        PMID: 25870266      PMCID: PMC4418889          DOI: 10.1073/pnas.1419162112

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  67 in total

1.  Immediate antiviral therapy appears to restrict resting CD4+ cell HIV-1 infection without accelerating the decay of latent infection.

Authors:  Nancie M Archin; Naveen K Vaidya; Joann D Kuruc; Abigail L Liberty; Ann Wiegand; Mary F Kearney; Myron S Cohen; John M Coffin; Ronald J Bosch; Cynthia L Gay; Joseph J Eron; David M Margolis; Alan S Perelson
Journal:  Proc Natl Acad Sci U S A       Date:  2012-05-29       Impact factor: 11.205

Review 2.  Therapeutic and prophylactic DNA vaccines for HIV-1.

Authors:  Lorenzo Antonio Ramirez; Tatiana Arango; Jean Boyer
Journal:  Expert Opin Biol Ther       Date:  2013-04       Impact factor: 4.388

3.  The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged anti-retroviral therapy.

Authors:  B Ramratnam; J E Mittler; L Zhang; D Boden; A Hurley; F Fang; C A Macken; A S Perelson; M Markowitz; D D Ho
Journal:  Nat Med       Date:  2000-01       Impact factor: 53.440

4.  Decay characteristics of HIV-1-infected compartments during combination therapy.

Authors:  A S Perelson; P Essunger; Y Cao; M Vesanen; A Hurley; K Saksela; M Markowitz; D D Ho
Journal:  Nature       Date:  1997-05-08       Impact factor: 49.962

5.  Modeling plasma virus concentration during primary HIV infection.

Authors:  M A Stafford; L Corey; Y Cao; E S Daar; D D Ho; A S Perelson
Journal:  J Theor Biol       Date:  2000-04-07       Impact factor: 2.691

6.  Long-term antiretroviral therapy initiated during primary HIV-1 infection is key to achieving both low HIV reservoirs and normal T cell counts.

Authors:  Laurent Hocqueloux; Véronique Avettand-Fènoël; Sophie Jacquot; Thierry Prazuck; Eric Legac; Adeline Mélard; Mohamadou Niang; Catherine Mille; Gwenaël Le Moal; Jean-Paul Viard; Christine Rouzioux
Journal:  J Antimicrob Chemother       Date:  2013-01-20       Impact factor: 5.790

7.  HIV-1 control after transient antiretroviral treatment initiated in primary infection: role of patient characteristics and effect of therapy.

Authors:  Cécile Goujard; Isabelle Girault; Christine Rouzioux; Camille Lécuroux; Christiane Deveau; Marie-Laure Chaix; Christine Jacomet; Amel Talamali; Jean-François Delfraissy; Alain Venet; Laurence Meyer; Martine Sinet
Journal:  Antivir Ther       Date:  2012-08-06

8.  Comparative analysis of measures of viral reservoirs in HIV-1 eradication studies.

Authors:  Susanne Eriksson; Erin H Graf; Viktor Dahl; Matthew C Strain; Steven A Yukl; Elena S Lysenko; Ronald J Bosch; Jun Lai; Stanley Chioma; Fatemeh Emad; Mohamed Abdel-Mohsen; Rebecca Hoh; Frederick Hecht; Peter Hunt; Ma Somsouk; Joseph Wong; Rowena Johnston; Robert F Siliciano; Douglas D Richman; Una O'Doherty; Sarah Palmer; Steven G Deeks; Janet D Siliciano
Journal:  PLoS Pathog       Date:  2013-02-14       Impact factor: 6.823

9.  Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI Study.

Authors:  Asier Sáez-Cirión; Charline Bacchus; Laurent Hocqueloux; Véronique Avettand-Fenoel; Isabelle Girault; Camille Lecuroux; Valerie Potard; Pierre Versmisse; Adeline Melard; Thierry Prazuck; Benjamin Descours; Julien Guergnon; Jean-Paul Viard; Faroudy Boufassa; Olivier Lambotte; Cécile Goujard; Laurence Meyer; Dominique Costagliola; Alain Venet; Gianfranco Pancino; Brigitte Autran; Christine Rouzioux
Journal:  PLoS Pathog       Date:  2013-03-14       Impact factor: 6.823

10.  Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.

Authors:  N M Archin; A L Liberty; A D Kashuba; S K Choudhary; J D Kuruc; A M Crooks; D C Parker; E M Anderson; M F Kearney; M C Strain; D D Richman; M G Hudgens; R J Bosch; J M Coffin; J J Eron; D J Hazuda; D M Margolis
Journal:  Nature       Date:  2012-07-25       Impact factor: 49.962

View more
  61 in total

Review 1.  Post-Treatment Controllers: Role in HIV "Cure" Research.

Authors:  Leslie R Cockerham; Hiroyu Hatano; Steven G Deeks
Journal:  Curr HIV/AIDS Rep       Date:  2016-02       Impact factor: 5.071

Review 2.  Kill: boosting HIV-specific immune responses.

Authors:  Lydie Trautmann
Journal:  Curr Opin HIV AIDS       Date:  2016-07       Impact factor: 4.283

3.  HIV-1 proviral landscapes distinguish posttreatment controllers from noncontrollers.

Authors:  Radwa Sharaf; Guinevere Q Lee; Xiaoming Sun; Behzad Etemad; Layla M Aboukhater; Zixin Hu; Zabrina L Brumme; Evgenia Aga; Ronald J Bosch; Ying Wen; Golnaz Namazi; Ce Gao; Edward P Acosta; Rajesh T Gandhi; Jeffrey M Jacobson; Daniel Skiest; David M Margolis; Ronald Mitsuyasu; Paul Volberding; Elizabeth Connick; Daniel R Kuritzkes; Michael M Lederman; Xu G Yu; Mathias Lichterfeld; Jonathan Z Li
Journal:  J Clin Invest       Date:  2018-08-20       Impact factor: 14.808

4.  Curing HIV: Moving Forward Faster.

Authors:  Marcella Flores; Rowena Johnston
Journal:  AIDS Res Hum Retroviruses       Date:  2016-02       Impact factor: 2.205

Review 5.  Novel AIDS therapies based on gene editing.

Authors:  Kamel Khalili; Martyn K White; Jeffrey M Jacobson
Journal:  Cell Mol Life Sci       Date:  2017-02-16       Impact factor: 9.261

6.  Disruption or Excision of Provirus as an Approach to HIV Cure.

Authors:  Keith R Jerome
Journal:  AIDS Patient Care STDS       Date:  2016-11-17       Impact factor: 5.078

Review 7.  The Biology of the HIV-1 Latent Reservoir and Implications for Cure Strategies.

Authors:  Lillian B Cohn; Nicolas Chomont; Steven G Deeks
Journal:  Cell Host Microbe       Date:  2020-04-08       Impact factor: 21.023

8.  Probabilistic control of HIV latency and transactivation by the Tat gene circuit.

Authors:  Youfang Cao; Xue Lei; Ruy M Ribeiro; Alan S Perelson; Jie Liang
Journal:  Proc Natl Acad Sci U S A       Date:  2018-11-19       Impact factor: 11.205

9.  Estimating Initial Viral Levels during Simian Immunodeficiency Virus/Human Immunodeficiency Virus Reactivation from Latency.

Authors:  Mykola Pinkevych; Christine M Fennessey; Deborah Cromer; Martin Tolstrup; Ole S Søgaard; Thomas A Rasmussen; Brandon F Keele; Miles P Davenport
Journal:  J Virol       Date:  2018-01-02       Impact factor: 5.103

Review 10.  Dual targeting of the thioredoxin and glutathione systems in cancer and HIV.

Authors:  Moran Benhar; Iart Luca Shytaj; Jonathan S Stamler; Andrea Savarino
Journal:  J Clin Invest       Date:  2016-05-02       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.